SCHEMBL16254754

SCHEMBL16254754

C#Cc1cccc(CC(=O)Nc2ccc(CN3CCN(CC)CC3)c(C(F)(F)F)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MKNK2 Q9HBH9 11/20 0.61
▸ MKNK1 Q9BUB5 8/20 0.61
▸ ABL1 P00519 5/20 0.61
▸ BCR P11274 5/20 0.61
▸ RET P07949 4/20 0.51
▸ KDR P35968 3/20 0.51
▸ KIT P10721 3/20 0.50
▸ PDGFRB P09619 1/20 0.50
▸ PDGFRA P16234 1/20 0.50
▸ FGFR2 P21802 1/20 0.50
▸ FLT3 P36888 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ HTT P42858 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ EPHA2 P29317 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16254749 0.88 MKNK2 (0.60) MKNK2MKNK1ABL1BCRRET
SCHEMBL15696849 0.87 RET (0.61) MKNK2MKNK1ABL1BCRRET
SCHEMBL15688171 0.86 MKNK2 (0.64) MKNK2MKNK1ABL1BCRRET
SCHEMBL16236572 0.85 KIT (0.63) ABL1BCRRETKDRKIT
SCHEMBL17182184 0.82 RET (0.66) MKNK2MKNK1ABL1BCRRET
SCHEMBL17182165 0.81 MKNK2 (0.73) MKNK2MKNK1ABL1BCRRET
SCHEMBL15785403 0.80 MKNK2 (0.65) MKNK2MKNK1ABL1BCRRET
SCHEMBL17181828 0.80 MKNK2 (0.66) MKNK2MKNK1ABL1BCRRET
SCHEMBL17181798 0.79 MKNK2 (0.67) MKNK2MKNK1ABL1BCRRET
SCHEMBL15688026 0.79 MKNK2 (0.56) MKNK2MKNK1ABL1BCRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 — — EP disclosed
EP-2997030-B1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2017-08-09 — — EP disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 — — US disclosed
US-9682083-B2 Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-20 — — US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 — — US disclosed
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-06-16 — — US disclosed
WO-2014184069-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166575-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS RET, DCK, PRKD2 MKNK2 144/4885MKNK1 153/4885ABL1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback